Results
Filtros
Cannabis in the Treatment of Skin Diseases: 3 Science-Backed Benefits
Studies show efficacy of cannabinoids in controlling inflammation, acne, and itching, while Anvisa evaluates expanding regulations for topical products
With inspirations ranging from American bluegrass to Gabriel García Márquez literature, entrepreneur points to "mirror" market for Brazil
The Australian medicinal cannabis market is consolidating as an international reference and inspiring discussions in Brazil
Public participation in Anvisa's regulatory agenda continues until September 15
Public consultation allows society to give opinions on the agency's priorities for the next two years; preliminary list does not include cannabis
Reblas Network includes cannabis product analysis; Brazil has 16 accredited laboratories
Published by Anvisa, the new resolution expands the scope of the network of analytical laboratories and reinforces the quality control of cannabis-based products in the country
Reblas Network includes cannabis product analysis; Brazil has 16 accredited laboratories
Published by Anvisa, the new resolution expands the scope of the network of analytical laboratories and reinforces the quality control of cannabis-based products in the country
Evolution and Challenges of Veterinary Medicine in Brazil in the Prescription of Medicinal Cannabis
Regulatory advances expand access to cannabis treatments for animals, but veterinarians still face barriers in prescribing and regulating products
Anvisa Regulatory Agenda 2026 - 2027 opens space for society suggestions, including on cannabis
Population and regulated sectors have the opportunity to indicate topics of interest for the next biennium
Ministry of Health and ANVISA receive Technical Note identifying 481 barriers to scientific development of cannabis in Brazil
Document developed by a group with 31 Brazilian academic and research institutions points out regulatory barriers and suggests an agile framework to strengthen the scientific and technological sector
New Anvisa directors move forward for Senate confirmation hearing
Social Affairs Committee confirms Safatle, Cerqueira, and Cardoso's names, in a moment of important reforms at the agency
Anvisa Nominees' Hearing Scheduled in Senate
Social Affairs Committee to analyze four names for leadership positions in health agencies
Ways to Access Cannabis Products in Brazil
01/18/2023Understand the step-by-step process to acquire plant derivatives for medicinal purposes
Cannabis Connection 2025 brings together experts to discuss the future of cannabis in Brazil
09/22/2025Check out the confirmed names: Beatriz Marti Emygdio, Filipe Campos, Tarso Araujo, and João Paulo Silvério Perfeito will be among the specialists participating in the event in São Paulo
Globo Rural covers medicinal cannabis and industrial hemp in special report
Debates on medicinal cannabis continue deeply at Cannabis Connection 2025 in November and at the Brazilian Medicinal Cannabis Congress in May 2026, both in São Paulo.
SUS and Health Insurance Plans
01/01/2024Learn How to Access Cannabis Products Through the Unified Health System and Understand the Obligations of Health Insurance Providers
Professor Advocates for Inclusion of Physical Therapists in Cannabis-Based Treatment
COFFITO Ruling No. 735/2024 authorizes physical therapists with specific training to prescribe medications and supplies; however, Anvisa recognizes only doctors and dentists as prescribers of cannabis for medicinal purposes
How RDC 660 ensures diversified products and support for doctors in different diseases
Paula Scanapieco, a specialist in medical cannabis logistics, speaks on Deusa Cast about the importance of RDC 660, product quality, and the role of companies in providing reliable information to doctors and patients in Brazil
Request Authorization to Import Cannabis-Derived Products
01/01/2024Follow the instructions to initiate the import process through RDC 660
More than 500 companies offer cannabis products to Brazil through importation; products now exceed 600
Anvisa points out the USA as the main supplier, followed by Canada, Colombia, and Uruguay
Anvisa prohibits eight cannabis products due to lack of registration
The agency determined the suspension of the commercialization and advertising of all items from the brands Golden CBD Plus and Golden CBD+ Nanotech in the national territory.
From Pain to Well-being: The New Era of Dentistry with Cannabis
Discover in Sechat 2024's free e-book how medical cannabis is revolutionizing dentistry, offering pain relief, inflammation control, and well-being during treatments.